The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
Open accessAbstract
BACKGROUND: Previous studies have suggested that the use of nonsteroidal antiinflammatory drugs (NSAIDs) may help to prevent Alzheimer's disease. The results, however, are inconsistent. METHODS: We studied the association between the use of NSAIDs and Alzheimer's disease and vascular dementia in a prospective, population-based cohort study of 6989 subjects 55 years of age or older who were free of dementia at base line, in 1991. To detect new cases of dementia, follow-up screening was performed in 1993 and 1994 and again in 1997 through 1999. The risk of Alzheimer's disease was estimated in relation to the use of NSAIDs as documented in pharmacy records. We defined four mutually exclusive categories of use: nonuse, short-term use (1 month or less of cumulative use), intermediate-term use (more than 1 but less than 24 months of cumulative use), and long-term use (24 months or more of cumulative use). Adjustments were made by Cox regression analysis for age, sex, education, smoking status, and the use or nonuse of salicylates, histamine Hz-receptor antagonists, antihypertensive agents, and hypoglycemic agents. RESULTS: During an average follow-up period of 6.8 years, dementia developed in 394 subjects, of whom 293 had Alzheimer's disease, 56 vascular dementia, and 45 other types of dementia. The relative risk of Alzheimer's disease was 0.95 (95 percent confidence interval, 0.70 to 1.29) in subjects with short-term use of NSAIDs, 0.83 (95 percent confidence interval, 0.62 to 1.11) in those with intermediate-term use, and 0.20 (95 percent confidence interval, 0.05 to 0.83) in those with long-term use. The risk did not vary according to age. The use of NSAIDs was not associated with a reduction in the risk of vascular dementia. CONCLUSIONS: The long-term use of NSAIDs may protect against Alzheimer's disease but not against vascular dementia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The recognition that a robust inflammatory response contributes to AD also fuelled the discovery that long-term treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) reduced the risk for AD, delayed disease onset, and slowed cognitive decline (McGeer et al., 1996;Stewart et al., 1997;in t' in t'Veld et al., 2001).”
From PPARγ/RXRα-Induced and CD36-Mediated Microglial Amyloid-β Phagocytosis Results in Cognitive Improvement in Amyloid Precursor Protein/Presenilin 1 Mice (2012) · cites this paper as in t'Veld et al., 2001
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Román, G. C., Tatemichi, T. K., Erkinjuntti, T., Cummings, J. L., Masdeu, J. C., Garcia, J. H., Amaducci, L., Orgogozo, J.-M., Brun, A., Hofman, A., et al. (1993) · Neurology · doi:10.1212/wnl.43.2.250 · Cited by 4,921
The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
Roth, M., Tym, E., Mountjoy, C. Q., Huppert, F. A., Hendrie, H., Verma, S., & Goddard, R. (1986) · British Journal of Psychiatry · doi:10.1192/bjp.149.6.698 · Cited by 2,090
MCGEER, P., & MCGEER, E. (1995) · Brain Research Reviews · doi:10.1016/0165-0173(95)00011-9 · Cited by 1,287
Risk of Alzheimer's disease and duration of NSAID use
Stewart, W. F., Kawas, C., Corrada, M., & Metter, E. J. (1997) · Neurology · doi:10.1212/wnl.48.3.626 · Cited by 1,132
Determinants of disease and disability in the elderly: The Rotterdam elderly study
Albert Hofman, D., Grobbee, D. E., de Jong, P. T. V. M., & Ouweland, F. A. V. D. (1991) · European Journal of Epidemiology · doi:10.1007/bf00145007 · Cited by 1,120
Flagged first, then by citations
Research works printed but not linked: 4
- Brooks W, 1998, Neurobiol Aging, 19, S140
- Kukull WA, 1994, Neurology, 44, A237
- Cornelius C, 1998, Neurobiol Aging, 19, S28
- Time-varying explanatory variables. In: Clayton D, Hills M. Statistical models in epidemiology. Oxford, England: Oxford University Press, 1993:307-18.
Cited by
Sorted by citations
Items 301–400 of 1,000
Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia
Jordan, F., Quinn, T. J., McGuinness, B., Passmore, P., Kelly, J. P., Smith, C. T., Murphy, K., & Devane, D. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011459.pub2 · Cited by 102
Mitochondria-Derived Damage-Associated Molecular Patterns in Neurodegeneration
Wilkins, H. M., Weidling, I. W., Ji, Y., & Swerdlow, R. H. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00508 · Cited by 102
Chang, H., Kim, J., Lee, J.-C., Kim, W.-K., & Chun, H. S. (2013) · Journal of Medicinal Food · doi:10.1089/jmf.2012.2283 · Cited by 102
Lipid Signaling and Synaptic Plasticity
Sang, N., & Chen, C. (2006) · The Neuroscientist · doi:10.1177/1073858406290794 · Cited by 98
Sex differences in Alzheimer’s disease: Understanding the molecular impact
Toro, C. A., Zhang, L., Cao, J., & Cai, D. (2019) · Brain Research · doi:10.1016/j.brainres.2019.05.031 · Cited by 105
Grzanna, R., Phan, P. V., Polotsky, A., Lindmark, L., & Frondoza, C. G. (2004) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2004.10.1009 · Cited by 97
“Support for this hypothesis comes from epidemiologic data and clinical trials showing that prolonged use of anti-inflammatory agents significantly lowers the incidence and slows the progression of AD (in ’t Veld et al., 2001; Macken-zie and Munoz, 1998; McGeer et al., 1996; Stewart et al., 1997).”
Gasparini, L., Rusconi, L., Xu, H., Soldato, P. D., & Ongini, E. (2003) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02154.x · Cited by 97
“Several epidemiological studies (McGeer et al. 1996; In’t Veld et al. 2001; Lindsay et al. 2002; Zandi et al. 2002; Etminan et al. 2003) indicate that NSAIDs use reduces the risk of developing AD, slows the progression and decreases the severity of dementia.”
BackgroundGasic‐Milenkovic, J., Dukic‐Stefanovic, S., Deuther‐Conrad, W., Gärtner, U., & Münch, G. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02506.x · Cited by 87
A Blood-Based Algorithm for the Detection of Alzheimer’s Disease
O’Bryant, S. E., Xiao, G., Barber, R. C., Reisch, J., Hall, J. R., Cullum, C. M., Doody, R. S., Fairchild, T., Adams, P. M., Wilhelmsen, K. C., et al. (2011) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000330750 · Cited by 96
Flores, J., Noël, A., Foveau, B., Beauchet, O., & LeBlanc, A. C. (2020) · Nature Communications · doi:10.1038/s41467-020-18405-9 · Cited by 103
Jin, D., Lim, C. S., Sung, J., Choi, H. G., Ha, I., & Han, J. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.03.068 · Cited by 99
Effects of hormone therapy on brain morphology of healthy postmenopausal women
Boccardi, M., Ghidoni, R., Govoni, S. M., Testa, C., Benussi, L., Bonetti, M., Binetti, G. G., & Frisoni, G. B. (2006) · Menopause The Journal of The North American Menopause Society · doi:10.1097/01.gme.0000196811.88505.10 · Cited by 97
Drug Insight: effects mediated by peroxisome proliferator-activated receptor-γ in CNS disorders
Heneka, M. T., Landreth, G. E., & Hüll, M. (2007) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0586 · Cited by 97
Study of interleukin-6 production in Alzheimer's disease.
Cojocaru, I. M., Cojocaru, M., Miu, G., & Sapira, V. (2011) · PubMed · Cited by 96
Reid, M. C., Bennett, D. A., Chen, W., Eldadah, B. A., Farrar, J. T., Ferrell, B. A., Gallagher, R. M., Hanlon, J. T., Herr, K., Horn, S. D., et al. (2011) · Pain Medicine · doi:10.1111/j.1526-4637.2011.01211.x · Cited by 95
Morihara, T., Teter, B., Yang, F., Lim, G. P., Boudinot, S. G., Boudinot, F. D., Frautschy, S. A., & Cole, G. M. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300668 · Cited by 96
Collins-Praino, L. E., & Corrigan, F. (2017) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2016.09.027 · Cited by 95
Zhu, S., Wang, J., Zhang, Y., He, J., Kong, J., Wang, J., & Li, X. (2017) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12677 · Cited by 96
Type-I interferon pathway in neuroinflammation and neurodegeneration: focus on Alzheimer’s disease
Taylor, J. M., Moore, Z., Minter, M. R., & Crack, P. J. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1745-4 · Cited by 94
Vijayalakshmi, D., Ramamurthy, D., Jayaveni, S., Panneerselvam, J., Rose, C., & Mandal, A. B. (2012) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2012.02.040 · Cited by 94
“The utility of these powerful drugs is limited due to their gastrointestinal (GI) side-effects, notably peptic ulceration and GI bleeding (Veld et al., 2001; Cook et al., 2005; Chan et al., 2008).”
BackgroundMolecular targets of non-steroidal anti-inflammatory drugs in neurodegenerative diseases
Lleo, A., Galea, E., & Sastre, M. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-6516-1 · Cited by 93
Inflammatory prostaglandin E2 signaling in a mouse model of Alzheimer disease
Shi, J., Wang, Q., Johansson, J. U., Liang, X., Woodling, N. S., Priyam, P. G., Loui, T., Merchant, M. J., BREYER, R. M., Montine, T. J., et al. (2012) · Annals of Neurology · doi:10.1002/ana.23677 · Cited by 93
Candore, G., Bulati, M., Caruso, C., Castiglia, L., Colonna‐Romano, G., Bona, D. D., Duro, G., Lio, D., Matranga, D., Pellicanò, M., et al. (2010) · Rejuvenation Research · doi:10.1089/rej.2009.0993 · Cited by 95
Disease-Modifying Therapies in Alzheimer???s Disease
ll, M. H., Berger, T., & Heneka, M. T. (2006) · Drugs · doi:10.2165/00003495-200666160-00004 · Cited by 95
The Inflammatory Response in Alzheimer's Disease
Rogers, J. (2008) · Journal of Periodontology · doi:10.1902/jop.2008.080171 · Cited by 92
CT Angiography and CT Perfusion Imaging
Lev, M. H., & González, R. (2002) · Elsevier eBooks · doi:10.1016/b978-012693019-1/50019-8 · Cited by 91
Sulindac improves memory and increases NMDA receptor subunits in aged Fischer 344 rats
Mesches, M. H., Gemma, C., Veng, L., Allgeier, C. A., Young, D. A., Browning, M. D., & Bickford, P. C. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(03)00116-7 · Cited by 91
“While chronic use of NSAIDs decreases the risk for AD [28], the cognitive effects of NSAIDs in the elderly are not well understood.”
BackgroundA Review: Treatment of Alzheimer’s Disease Discovered in Repurposed Agents
Appleby, B. S., Nacopoulos, D. A., Milano, N. J., Zhong, K., & Cummings, J. L. (2013) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000345791 · Cited by 90
Interleukin-18, From Neuroinflammation to Alzheimers Disease
Bossù, P., Ciaramella, A., Salani, F., Vanni, D., Palladino, I., Caltagirone, C., & Scapigliati, G. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210794519147 · Cited by 89
“In addition, some epidemiological and prospective population-based studies have suggested that the chronic use of non-steroidal antiinflammatory drugs (NSAIDs) could be protective against AD [55, 56] by means of a number of molecular mechanisms that include the lowering of pathogenic A peptide production [57].”
BackgroundSalech, F., Ponce, D. P., Paula-Lima, A. C., SanMartín, C. D., & Behrens, M. I. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00255 · Cited by 92
Eikelenboom, P., Veerhuis, R., van Exel, E. R., Hoozemans, J. J. M., Rozemüller, A. J. M., & van Gool, W. A. (2011) · Current Alzheimer Research · doi:10.2174/156720511795256080 · Cited by 87
“In contrast to these therapeutic trials, epidemiological studies show that NSAIDS could be beneficial as prevention as found in the Rotterdam Study [101] and in a recent re-analysis of the ADAPT-study [102].”
ResultAlzheimer’s disease and its treatment–yesterday, today, and tomorrow
Kim, A. Y., Jerdi, S. A., MacDonald, R., & Triggle, C. R. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1399121 · Cited by 99
Nitric oxide in neurodegeneration: potential benefits of non-steroidal anti-inflammatories
Doherty, G. H. (2011) · Neuroscience Bulletin · doi:10.1007/s12264-011-1530-6 · Cited by 91
Franciosi, S., Choi, H. B., Kim, S. U., & McLarnon, J. G. (2004) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2004.10.006 · Cited by 87
“The progressive pathology associated with AD may be a consequence of local inflammatory reactions, and results from clinical studies have indicated that prolonged treatment with anti-inflammatory drugs can reduce the incidence of dementia (Rogers et al., 1993; In t’ Veld et al., 2001).”
Drug development for Alzheimer’s disease: Review
Lao, K., Ji, N., Zhang, X., Qiao, W., Tang, Z., & Gou, X. (2019) · Journal of drug targeting · doi:10.1080/1061186x.2018.1474361 · Cited by 86
“The relative risk of AD was largely reduced for those using NSAIDs longer than 24months [84].”
BackgroundNeurodegenerative diseases: The immunological perspective
Molteni, M., & Rossetti, C. (2017) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2017.11.002 · Cited by 87
Mohri, I., Kadoyama, K., Kanekiyo, T., Sato, Y., Kagitani‐Shimono, K., Saito, Y., Suzuki, K., Kudo, T., Takeda, M., Urade, Y., et al. (2007) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/01.jnen.0000240472.43038.27 · Cited by 87
Wenk, G. L., McGann-Gramling, K. R., Hauss‐Wegrzyniak, B., Ronchetti, D., Maucci, R., Rosi, S., Gasparini, L., & Ongini, E. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02359.x · Cited by 85
“Furthermore, considerable epidemiological evidence also predicts that long-term use of anti-inflammatory drugs reduces the incidence and slows the progression of AD (Stewart et al. 1997; In ‘T Veld et al. 2001; Zandi et al. 2002).”
BackgroundMattson, M. P., Lee, J., & Chan, S. L. (2002) · NeuroMolecular Medicine · doi:10.1385/nmm:2:1:29 · Cited by 83
Insulin signalling in Alzheimer′s disease and diabetes: from epidemiology to molecular links
Ribé, E. M., & Lovestone, S. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12534 · Cited by 88
Cyclooxygenase-1 null mice show reduced neuroinflammation in response to β-amyloid
Choi, S., & Bosetti, F. (2009) · Aging · doi:10.18632/aging.100021 · Cited by 87
Cole, G. M., & Frautschy, S. A. (2010) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152710791011991 · Cited by 85
Lee, M., McGeer, E. G., & McGeer, P. L. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.07.024 · Cited by 85
Gajraj, N. M. (2003) · Anesthesia & Analgesia · doi:10.1213/01.ane.0000061461.55712.c5 · Cited by 83
Münch, G. W., Gasic‐Milenkovic, J., Dukić-Stefanović, S., Kuhla, B., Heinrich, K., Riederer, P. F., Huttunen, H. J., Founds, H., & Sajithlal, G. B. (2003) · Experimental Brain Research · doi:10.1007/s00221-003-1389-5 · Cited by 82
“Its relevance for the disease progression is also supported by epidemiological studies, which have shown a reduced risk of AD among long-term users of anti-inflammatory drugs (Beard et al. 1998; in t’ Veld et al. 2001).”
Resultd’Abramo, C., Massone, S., Zingg, J.-M., Pizzuti, A., Marambaud, P., Piccola, B. D., Azzi, A., Marinari, U. M., Pronzato, M. A., & Ricciarelli, R. (2005) · Biochemical Journal · doi:10.1042/bj20050560 · Cited by 81
High mobility group box protein‐1 inhibits microglial Aβ clearance and enhances Aβ neurotoxicity
Takata, K., Kitamura, Y., Tsuchiya, D., Kawasaki, T., Taniguchi, T., & Shimohama, S. (2004) · Journal of Neuroscience Research · doi:10.1002/jnr.20340 · Cited by 82
Immunological Aetiology of Major Psychiatric Disorders
Sperner‐Unterweger, B. (2005) · Drugs · doi:10.2165/00003495-200565110-00004 · Cited by 83
Predictors of long-term cognitive outcome in Alzheimer's disease
Wattmo, C., Wallin, Å. K., Londos, E., & Minthon, L. (2011) · Alzheimer s Research & Therapy · doi:10.1186/alzrt85 · Cited by 81
Targeting neuroinflammation in Alzheimer’s disease: evidence for NSAIDs and novel therapeutics
Deardorff, W. J., & Grossberg, G. T. (2016) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2016.1200972 · Cited by 85
Olive Oil Phenols as Promising Multi-targeting Agents Against Alzheimer’s Disease
Rigacci, S. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-18365-7_1 · Cited by 84
van Leeuwen, R., Vingerling, J. R., Hofman, A., de Jong, P. T. V. M., & Stricker, B. H. C. (2003) · BMJ · doi:10.1136/bmj.326.7383.255 · Cited by 81
Self-citationMasitinib for the treatment of mild to moderate Alzheimer’s disease
Folch, J., Petrov, D., Ettcheto, M., Pedrós, I., Abad, S., Beas-Zarate, C., Lazarowski, A., Marin, M., Olloquequi, J., Auladell, C., et al. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1045419 · Cited by 80
Kaduševičius, E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126637 · Cited by 85
Indomethacin protects against neurodegeneration caused by MPTP intoxication in mice.
Kurkowska-Jastrzębska, I., Babiuch, M., Joniec, I., Przybyłkowski, A., Członkowski, A., & Członkowska, A. (2002) · International Immunopharmacology · doi:10.1016/s1567-5769(02)00078-4 · Cited by 80
Licastro, F., Porcellini, E., Caruso, C., Lio, D., & Corder, E. H. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.07.007 · Cited by 78
Kummer, M. P., & Heneka, M. T. (2008) · PPAR Research · doi:10.1155/2008/403896 · Cited by 78
Prati, F., Uliassi, E., & Bolognesi, M. L. (2014) · MedChemComm · doi:10.1039/c4md00069b · Cited by 77
DNA Hypomethylation in Blood Links B3GALT4 and ZADH2 to Alzheimer’s Disease
Madrid, A., Hogan, K. J., Papale, L. A., Clark, L. R., Asthana, S., Johnson, S. C., & Alisch, R. S. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-180592 · Cited by 77
Nonsteroidal Anti-Inflammatory Drugs and the Risk of Parkinson Disease
Bornebroek, M., de Lau, L. M. L., Haag, M. D. M., Koudstaal, P. J., Albert Hofman, D., Stricker, B. H. C., & Breteler, M. M. B. (2007) · Neuroepidemiology · doi:10.1159/000108110 · Cited by 77
Self-citationAlcohol, wine and mental health: focus on dementia and stroke
Pinder, R. M., & Sandler, M. (2004) · Journal of Psychopharmacology · doi:10.1177/0269881104047272 · Cited by 77
“…a wealth of laboratory evidence that inflammatory mechanisms contribute to the neuronal damage in Alzheimer’s disease (Aisen, 1997; Akiyama et al., 2000), while the long term use of non-steroidal antiinflammatory drugs (NSAIDs) may protect against development of dementia (in ‘t Veld et al., 2001).”
BackgroundSiddiqui, S. S., Springer, S. A., Verhagen, A., Sundaramurthy, V., Alisson‐Silva, F., Jiang, W., Ghosh, P., & Varki, A. P. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.799346 · Cited by 77
Current Therapeutic Options for Alzheimers Disease
Lleó, A. (2007) · Current Genomics · doi:10.2174/138920207783769549 · Cited by 77
Nonsteroidal anti-inflammatory drug use and Alzheimer's disease risk: the MIRAGE Study
Yip, A. G., Green, R. C., Huyck, M., Cupples, L. A., Farrer, L. A., & for the MIRAGE Study Group (2005) · BMC Geriatrics · doi:10.1186/1471-2318-5-2 · Cited by 79
Alzheimer's Disease: Neuropathologic Findings and Recent Advances in Imaging
Norfray, J. F., & Provenzale, J. M. (2004) · American Journal of Roentgenology · doi:10.2214/ajr.182.1.1820003 · Cited by 79
Interleukin-6, β-amyloid peptide and NMDA interactions in rat cortical neurons
Qiu, Z., & Gruol, D. L. (2003) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(03)00158-9 · Cited by 79
Perturbations in calcium‐mediated signal transduction in microglia from Alzheimer's disease patients
McLarnon, J. G., Choi, H. B., Lue, L., Walker, D. G., & Kim, S. U. (2005) · Journal of Neuroscience Research · doi:10.1002/jnr.20487 · Cited by 73
“Neurodegeneration in AD is accompanied by brain inflammation and in vivo studies have suggested that nonsteroidal antiinflammatory drugs (NSAIDs) can slow the progression of disease (Stewart et al., 1997; in t’ Veld et al., 2001).”
BackgroundPlasma Aβ42 correlates positively with increased body fat in healthy individuals
Balakrishnan, K., Verdile, G., Mehta, P. D., Beilby, J. P., Nolan, D. A., Galvao, D. A., Newton, R. U., Gandy, S., & Martins, R. N. (2005) · Journal of Alzheimer s Disease · doi:10.3233/jad-2005-8305 · Cited by 76
“anti-inflammatory drugs on AD risk [29,48,78].”
Bioactive Nutrients and Nutrigenomics in Age-Related Diseases
Rescigno, T., Micolucci, L., Tecce, M. F., & Capasso, A. (2017) · Molecules · doi:10.3390/molecules22010105 · Cited by 75
Poon, C. H., Wang, Y., Fung, M., Zhang, C., & Lim, L. W. (2020) · Aging and Disease · doi:10.14336/ad.2019.1026 · Cited by 76
Kunz, T., Marklund, N., Hillered, L., & Oliw, E. H. (2002) · Journal of Neurotrauma · doi:10.1089/089771502760341965 · Cited by 74
“Thirdly, a prospective epidemiological study suggests that regular treatment with nonsteroidal antiinflammatory drugs might significantly reduce the risk of Alzheimer’s disease (In’t Veld et al., 2001).”
Immune-Inflammatory Responses and Oxidative Stress in Alzheimers Disease: Therapeutic Implications
Bona, D. D., Scapagnini, G., Candore, G., Castiglia, L., Colonna‐Romano, G., Duro, G., Nuzzo, D., Iemolo, F., Lio, D., Pellicanò, M., et al. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210790883769 · Cited by 76
Cyclooxygenase-2 expression during rat neocortical development and in Rett syndrome
Kaufmann, W. E., Worley, P. F., Taylor, C. V., Bremer, M. E., & Isakson, P. C. (1997) · Brain and Development · doi:10.1016/s0387-7604(96)00047-2 · Cited by 73
Nelson, M. R., Reid, C. M., Beilin, L. J., Donnan, G. A., Johnston, C. I., Krum, H., Storey, E., Tonkin, A. M., & McNeil, J. J. (2003) · Drugs & Aging · doi:10.2165/00002512-200320120-00004 · Cited by 73
Neuroinflammation, microglia and implications for anti-inflammatory treatment in Alzheimer’s disease
Krause, D. L., & Müller, N. (2010) · International Journal of Alzheimer's Disease · doi:10.4061/2010/732806 · Cited by 168
Involvement of Prostaglandin E2 in Production of Amyloid-β Peptides Both in Vitro and in Vivo
Hoshino, T., Nakaya, T., Homan, T., Tanaka, K., Sugimoto, Y., Araki, W., Narita, M., Narumiya, S., Suzuki, T., & Mizushima, T. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m703087200 · Cited by 74
Nelson, M. R., Reid, C. M., Ames, D. J., Beilin, L. J., Donnan, G. A., Gibbs, P., Johnston, C. I., Krum, H., Storey, E., Tonkin, A. M., et al. (2008) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2008.tb01932.x · Cited by 68
Alzheimer’s disease and type 2 diabetes via chronic inflammatory mechanisms
Mushtaq, G., Khan, J. A., Kumosani, T. A., & Kamal, M. A. (2014) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2014.05.003 · Cited by 75
“The greatest risk reduction to develop AD was seen among those with extended exposure to NSAIDs (In’t Veld et al., 2001; Zandi et al., 2002; Aisen et al., 2002).”
In vivo evidence for microglial activation in neurodegenerative dementia
Cagnin, A., Kassiou, M., Meikle, S. R., & Banati, R. B. (2006) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2006.00694.x · Cited by 71
Integrated communications between cyclooxygenase‐2 and Alzheimer's disease
Guan, P.-P., & Wang, P. (2018) · The FASEB Journal · doi:10.1096/fj.201800355rrrr · Cited by 70
Rentzos, M., Zoga, M., Paraskevas, G. P., Kapaki, E., Rombos, A., Nikolaou, C., Tsoutsou, A., & Vassilopoulos, D. (2006) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988706286226 · Cited by 65
Horváth, I., Jia, X., Johansson, P., Wang, C., Moskalenko, R., Steinau, A., Forsgren, L., Wågberg, T., Svensson, J., Zetterberg, H., et al. (2015) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00265 · Cited by 71
Qian, M., Shen, X., & Wang, H. (2015) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-015-0232-4 · Cited by 71
Characterization of Scavengers of γ-Ketoaldehydes That Do Not Inhibit Prostaglandin Biosynthesis
Zagol-Ikapitte, I. A., Amarnath, V., Bala, M., Roberts, L. J., Oates, J. A., & Boutaud, O. G. (2009) · Chemical Research in Toxicology · doi:10.1021/tx900407a · Cited by 68
Huang, X., Chen, Y., Zhang, H., Ma, Q., Zhang, Y., & Xu, H. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.10.007 · Cited by 68
Silvestrelli, G., Lanari, A., Parnetti, L., Tomassoni, D., & Amenta, F. (2005) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2005.09.018 · Cited by 73
Hein, A. M., Stutzman, D. L., Bland, S. T., Barrientos, R. M., Watkins, L. R., Rudy, J. W., & Maier, S. F. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2007.10.003 · Cited by 68
Ishikawa, A., Tokunaga, M., Maeda, J., Minamihisamatsu, T., Shimojo, M., Takuwa, H., Ono, M., Ni, R., Hirano, S., Kuwabara, S., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170509 · Cited by 69
Novel therapeutic strategies provide the real test for the amyloid hypothesis of Alzheimer's disease
Dominguez, D. I., & Strooper, B. D. (2002) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(02)02038-2 · Cited by 68
Gasparini, L., Ongini, E., Wilcock, D. M., & Morgan, D. (2005) · Brain Research Reviews · doi:10.1016/j.brainresrev.2004.12.029 · Cited by 68
Nonsteroidal Anti-Inflammatory Drug Use and the Risk for Alzheimer???s Disease
Launer, L. J. (2003) · Drugs · doi:10.2165/00003495-200363080-00001 · Cited by 69
Self-citationLlorens-Martín, M., Jurado‐Arjona, J., Fuster-Matanzo, A., Hernández, F., Rábano, A., & Ávila, J. (2014) · Translational Psychiatry · doi:10.1038/tp.2014.92 · Cited by 69
Biochemical Markers and Risk Factors of Alzheimers Disease
Flirski, M., & Sobów, T. (2005) · Current Alzheimer Research · doi:10.2174/1567205052772704 · Cited by 67
“Epidemiological investigations revealed a decreased incidence of AD in subjects protractedly using non-steroidal anti-inflammatory drugs [43,44], indirectly confirming the importance of inflammation in the pathogenesis of AD.”
BackgroundSynaptotoxicity in Alzheimer's Disease: The Wnt Signaling Pathway as a Molecular Target
Inestrosa, N. C., Varela‐Nallar, L., Grabowski, C. P., & Colombres, M. (2007) · IUBMB Life · doi:10.1080/15216540701242490 · Cited by 65
Topical Nonsteroidal Anti-Inflammatory Drugs for Macular Edema
Russo, A., Costagliola, C., Delcassi, L., Parmeggiani, F., Romano, M. R., dell’Omo, R., & Semeraro, F. (2013) · Mediators of Inflammation · doi:10.1155/2013/476525 · Cited by 69
“Therefore it seems reasonable to take strong measures to minimize the inflammatory process, possibly including the administration of both corticosteroids and NSAIDs together.”
BackgroundDisease modification in Parkinson's disease
Schapira, A. H. V. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00769-0 · Cited by 67
Anti-inflammatory and Immune Therapy for Alzheimers Disease: Current Status and Future Directions
Walker, D., & Lue, L.-F. (2007) · Current Neuropharmacology · doi:10.2174/157015907782793667 · Cited by 66
Neuroinflammation in Alzheimer's disease: an understanding of physiology and pathology
Obulesu, M., & Jhansilakshmi, M. (2013) · International Journal of Neuroscience · doi:10.3109/00207454.2013.831852 · Cited by 66
“Epidemiologic studies emphasize the inverse relationship between nonsteroidal antiinflammatory drugs (NSAIDs) exposure and risk for AD [28, 31–33].”
BackgroundUrrutia, P. J., Hirsch, É. C., González-Billault, C. E., & Núñez, M. T. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14005 · Cited by 68
Wang, C., Iashchishyn, I. A., Pansieri, J., Nyström, S., Klementieva, O. L., Kara, J. A., Horváth, I., Moskalenko, R., Rofougaran, R., Gouras, G. K., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-31141-x · Cited by 67
Metadata
- Authors
- in 't Veld, B. A., Ruitenberg, A., Hofman, A., Launer, L. J., van Duijn, C. M., Stijnen, T., Breteler, M. M. B., & Stricker, B. H. C.
- Affiliations
- Erasmus MC (NL)
- National Institutes of Health (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2001-11-22
- Volume
- 345
- Issue
- 21
- Pages
- 1515-1521
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2083556882
- Semantic Scholar
- 29c01ac52ec50618ec7b3b87ca55b707ca397434
- Cited by
- 1,196
- References
- 44
- Citations by year
- 2026: 13 · 2025: 14 · 2024: 18 · 2023: 23 · 2022: 26 · 2021: 33 · 2020: 23 · 2019: 40 · 2018: 38 · 2017: 28 · 2016: 40 · 2015: 49 · 2014: 49 · 2013: 39 · 2012: 50
- FWCI
- 52.61
- Type
- journal article
- Language
- en
- Open access
- green
- pure.eur.nl
- Licence
- other-oa
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- RePub (Erasmus University Rotterdam) (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Keywords
- nonsteroidal anti-inflammatory drugs, Alzheimer's disease, vascular dementia, dementia risk, long-term NSAID use, older adults
- MeSH terms
- Aged, Alzheimer Disease, Anti-Inflammatory Agents, Non-Steroidal, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Prospective Studies, Risk, Salicylates, Dementia, Vascular, Cohort Studies, Proportional Hazards Models
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
